

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-36. (Canceled)

37. (Original) A composition for detecting a cancer cell in a biological sample of a patient, said composition comprising:

- (a) a first oligonucleotide; and
- (b) a second oligonucleotide;

wherein said first oligonucleotide and said second oligonucleotide hybridize to a first polynucleotide and to a second polynucleotide, respectively; wherein said first polynucleotide is unrelated in nucleotide sequence from said second polynucleotide; and wherein said first polynucleotide and said second polynucleotide are tissue-specific polynucleotides of the cancer cell to be detected.

38. (Original) The composition of claim 37 wherein said first polynucleotide and said second polynucleotide are complementary tissue-specific polynucleotides of the tissue-type of said cancer cell.

39. (Currently Amended ) The composition of any one of claim 37 and claim 38 wherein said first polynucleotide and said second polynucleotide are selected from the group consisting of the polynucleotides depicted in ~~SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO: 75, and SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:32, and SEQ ID NO:76.~~

40. (Currently Amended )The composition of any one of claim 37 and claim 38 wherein said oligonucleotides are selected from the group consisting of oligonucleotides as disclosed in SEQ ID NO: 58 and 55-33-72.

41. (Original) A composition for detecting a cancer cell in a biological sample of a patient, said composition comprising:

- (a) a first oligonucleotide pair; and
- (b) a second oligonucleotide pair;

wherein said first oligonucleotide pair and said second oligonucleotide pair hybridize to a first polynucleotide (or complement thereof) and to a second polynucleotide (or complement thereof), respectively; wherein said first polynucleotide is unrelated in nucleotide sequence from said second polynucleotide; and wherein said first polynucleotide and said second polynucleotide are tissue-specific polynucleotides of the cancer cell to be detected.

42. (Original) The composition of claim 41 wherein said first polynucleotide and said second polynucleotide are complementary tissue-specific polynucleotides of the tissue-type of said cancer cell.

43. (Currently Amended ) The composition of any one of claim 41 and claim 42 wherein said first polynucleotide and said second polynucleotide are selected from the group consisting of the polynucleotides depicted in ~~SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO: 75 and, SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:32, and SEQ ID NO:76.~~

44. (Currently Amended) The composition of any one of claim 41 and claim 42 wherein said oligonucleotides are selected from the group consisting of oligonucleotides as disclosed in SEQ ID NOs: 33-7253, 54, 56, and 57.

45. (Currently Amended) A composition comprising an oligonucleotide primer or probe of between 15 and 100 nucleotides that comprises an oligonucleotide selected from the group consisting of oligonucleotides depicted in SEQ ID NOs: ~~33-72~~53-58.

46. (Currently Amended) The composition of claim 45 comprising an oligonucleotide primer or probe selected from the group consisting of oligonucleotides depicted in SEQ ID NOs: ~~33-72~~53-58.